NCT00388518View on ClinicalTrials.gov

A Study of Aleglitazar in Patients With Type 2 Diabetes

PHASE2CompletedINTERVENTIONAL
Enrollment

332

Participants

Timeline

Start Date

November 30, 2006

Primary Completion Date

March 31, 2008

Study Completion Date

March 31, 2008

Conditions
Diabetes Mellitus Type 2
Interventions
DRUG

Actos

45mg po daily

DRUG

Placebo

po daily

DRUG

aleglitazar

Administered po daily, at ascending doses with a starting dose (arm 1) of 0.05mg.

Trial Locations (55)

10126

Torino

10700

Mexico City

11000

Belgrade

11042

New Hyde Park

12462

Athens

16132

Genova

18000

Niš

20230

Aguascalientes

21229

Baltimore

27100

Pavia

30909

Augusta

31238

Chihuahua City

32626

Chiefland

33023

Hollywood

33401

West Palm Beach

34000

Kragujevac

34080

Durango

37604

Johnson City

38654

Olive Branch

40138

Bologna

42086

Pachuca

44340

Guadalajara

44650

Guadalajara

53100

Siena

56429

Thessaloniki

60611

Chicago

62250

Cuernavaca

66260

Monterrey

70809

Baton Rouge

80100

Napoli

83404

Idaho Falls

85006

Phoenix

85029

Phoenix

90211

Beverly Hills

92161

San Diego

92262

Palm Springs

99216

Spokane

100163

Ploieşti

117036

Moscow

125315

Moscow

129090

Moscow

129110

Moscow

129327

Moscow

197089

Saint Petersburg

197198

Saint Petersburg

400006

Cluj-Napoca

410038

Saratov

800352

Galati

08610

Hamilton

Unknown

Hong Kong

Bucharest

07026

Olbia

06126

Perugia

00133

Roma

020475

Bucharest

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT00388518 - A Study of Aleglitazar in Patients With Type 2 Diabetes | Biotech Hunter | Biotech Hunter